1. Home
  2. ADPT vs NAVI Comparison

ADPT vs NAVI Comparison

Compare ADPT & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • NAVI
  • Stock Information
  • Founded
  • ADPT 2009
  • NAVI 1973
  • Country
  • ADPT United States
  • NAVI United States
  • Employees
  • ADPT N/A
  • NAVI N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • NAVI Investment Bankers/Brokers/Service
  • Sector
  • ADPT Health Care
  • NAVI Finance
  • Exchange
  • ADPT Nasdaq
  • NAVI Nasdaq
  • Market Cap
  • ADPT 1.4B
  • NAVI 1.2B
  • IPO Year
  • ADPT 2019
  • NAVI N/A
  • Fundamental
  • Price
  • ADPT $10.38
  • NAVI $13.51
  • Analyst Decision
  • ADPT Strong Buy
  • NAVI Hold
  • Analyst Count
  • ADPT 7
  • NAVI 7
  • Target Price
  • ADPT $10.57
  • NAVI $13.64
  • AVG Volume (30 Days)
  • ADPT 1.3M
  • NAVI 548.6K
  • Earning Date
  • ADPT 07-31-2025
  • NAVI 07-23-2025
  • Dividend Yield
  • ADPT N/A
  • NAVI 4.75%
  • EPS Growth
  • ADPT N/A
  • NAVI N/A
  • EPS
  • ADPT N/A
  • NAVI 0.52
  • Revenue
  • ADPT $189,527,000.00
  • NAVI $699,000,000.00
  • Revenue This Year
  • ADPT $24.46
  • NAVI N/A
  • Revenue Next Year
  • ADPT $20.25
  • NAVI $2.85
  • P/E Ratio
  • ADPT N/A
  • NAVI $26.01
  • Revenue Growth
  • ADPT 8.61
  • NAVI N/A
  • 52 Week Low
  • ADPT $2.99
  • NAVI $10.53
  • 52 Week High
  • ADPT $10.87
  • NAVI $16.97
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 62.28
  • NAVI 53.15
  • Support Level
  • ADPT $9.90
  • NAVI $13.10
  • Resistance Level
  • ADPT $10.85
  • NAVI $14.00
  • Average True Range (ATR)
  • ADPT 0.48
  • NAVI 0.29
  • MACD
  • ADPT -0.02
  • NAVI -0.06
  • Stochastic Oscillator
  • ADPT 68.39
  • NAVI 45.81

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About NAVI Navient Corporation

Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.

Share on Social Networks: